Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Dementia Alzheimer's Type
Interventions
Sargramostim GZ402664, Placebo, Florbetapir F18
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, [11C]-PIB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

NCT01565343
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more
Conditions
Progressive Cognitive Decline
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 14 more
Conditions
Alzheimer Disease
Interventions
LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Healthy Volunteers

NCT01564706
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Jenkintown, Pennsylvania
Conditions
Progressive Supranuclear Palsy, Alzheimer Disease, Healthy Volunteers
Interventions
[18F]MNI-952, [18F]Florbetapir
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958, [18F]Florbetapir, DaTscan
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Alzheimer's Disease
Interventions
[11C]PIB
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

NCT02051764
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Florbetapir F 18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Boston, Massachusetts + 1 more
Conditions
Alzheimer Disease
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Definity, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid
Device · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)

NCT02759887
Conditions
Down Syndrome, Alzheimer's Dementia
Interventions
biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy
Procedure · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Phase 4 Interventional Results available

The Feasibility of Florbetapir Quantitation

NCT01946243
Conditions
Alzheimers Disease
Interventions
Florbetapir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Parkinson's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions
Florbetapir, Flortaucipir
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Completed Phase 4 Interventional Results available

Evaluation of Reader Training Processes

NCT02051790
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

NCT05164536
Conditions
Alzheimer Disease
Interventions
Amyvid
Drug
Lead sponsor
Invicro
Other
Eligibility
70 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789
Conditions
Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Alzheimer Disease
Interventions
[18F]P16-129
Drug
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Phase 3 Interventional Accepts healthy volunteers

Biomarker Exploration in Aging, Cognition and Neurodegeneration

NCT03860857
Conditions
Alzheimer Disease, Cognitive Impairment, Cognitive Decline
Interventions
Amyloid PET scan, Tau PET scan using MK-6240, Neurocognitive testing, MRI
Radiation · Drug · Behavioral + 1 more
Lead sponsor
University of California, Irvine
Other
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Irvine, California
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Conditions
Alzheimer Disease, Parkinson Disease, Healthy Volunteers
Interventions
[18F]MNI-1126
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut